AstraZeneca
158,62 $Variación respecto al cierre anterior: −1,77 %Variación absoluta: −2,85 $
Últimas noticias
Titulares en el idioma original de la fuente.
- AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab (se abre en una pestaña nueva)
- AstraZeneca, Daiichi Partner With Summit on Cancer-Drug Trials (se abre en una pestaña nueva)
- AstraZeneca, Daiichi Sankyo and Summit Therapeutics Plan Datroway–Ivonescimab Combination Trials (se abre en una pestaña nueva)
- AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (se abre en una pestaña nueva)
- AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo (se abre en una pestaña nueva)
- AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types (se abre en una pestaña nueva)
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (se abre en una pestaña nueva)
- Hong Kong needs new funding model to attract global drug makers: AstraZeneca (se abre en una pestaña nueva)
- 700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 (se abre en una pestaña nueva)
- AstraZeneca slips Wednesday, underperforms market (se abre en una pestaña nueva)
- AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (se abre en una pestaña nueva)
- AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (se abre en una pestaña nueva)
- Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge (se abre en una pestaña nueva)
- AstraZeneca Dealt Latest Loss in Arkansas Drug Discount Case (se abre en una pestaña nueva)
- AstraZeneca commits $2bn to advance ADC combination medicines for cancer (se abre en una pestaña nueva)
- AstraZeneca (LSE:AZN) Wins FDA Priority Review For IMFINZI In Bladder Cancer (se abre en una pestaña nueva)
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll (se abre en una pestaña nueva)
- Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing? (se abre en una pestaña nueva)
- AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment (se abre en una pestaña nueva)
- AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up (se abre en una pestaña nueva)
- AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination (se abre en una pestaña nueva)
- Vital Signs: AstraZeneca's $2B seat at Summit's table (se abre en una pestaña nueva)
- Physician Views Results: European pulmonologists see AstraZeneca's Trixeo as another option in asthma (se abre en una pestaña nueva)
- Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note (se abre en una pestaña nueva)
- AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck (se abre en una pestaña nueva)
- AstraZeneca Pays $2 Billion To Take On Pfizer, Merck, Bristol (se abre en una pestaña nueva)
- A $2 Billion Reason Why AstraZeneca Stock Is Down Today (se abre en una pestaña nueva)
- AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug (se abre en una pestaña nueva)
- AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says (se abre en una pestaña nueva)
- Summit Shares Jump on $2B Strategic Investment From AstraZeneca (se abre en una pestaña nueva)